TG Therapeutics

YTD

ALL

Trade TG Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.

CEO

Michael Sean Weiss

CEOMichael Sean Weiss

Employees

338

Employees338

Headquarters

Morrisville, North Carolina

HeadquartersMorrisville, North Carolina

Founded

1993

Founded1993

Employees

338

Employees338

TGTX Key Statistics

Market cap

5.92B

Market cap5.92B

Price-Earnings ratio

149.84

Price-Earnings ratio149.84

Dividend yield

—

Dividend yield—

Average volume

1.84M

Average volume1.84M

High today

$37.58

High today$37.58

Low today

$36.31

Low today$36.31

Open price

$37.00

Open price$37.00

Volume

1.68M

Volume1.68M

52 Week high

$46.48

52 Week high$46.48

52 Week low

$16.65

52 Week low$16.65

TGTX News

Simply Wall St 6d

Have Insiders Sold TG Therapeutics Shares Recently?

Anyone interested in TG Therapeutics, Inc. ( ) should probably be aware that the Independent Director, Yann Echelard, recently divested US$369k worth of shares...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

Sell

12.5%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.